FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896812842> ?p ?o ?g. }

• W2896812842 abstract "Background: The need to identify biomarkers that predict benefit to checkpoint inhibitor therapies has led to the discovery and development of tumor mutational burden (TMB), a measure of potential tumor neoantigenicity derived from tissue biopsies that has shown clinical utility across a range of tumor types. A significant fraction of patients, however, are not candidates for tissue biopsies, presenting the need for blood-based methods to determine TMB. Here we describe the development of an assay to identify TMB from cell-free DNA derived from blood (bTMB). We present the analytic validation and clinical feasibility data that support the application of bTMB in a prospective clinical trial, BFAST (NCT03178552), evaluating the anti-PD-L1 agent atezolizumab in patients with non-small cell lung cancer (NSCLC). Methods: The bTMB assay surveys somatic base substitutions down to 0.5% allele frequency across 394 genes from as little as 1% tumor content in a cell free DNA (cfDNA) sample derived from blood. Analytic validation was focused on establishing accuracy and precision of the bTMB measurement, as well as the minimum amount of cell-free and circulating tumor DNA required to make precise and reliable bTMB calls. The accuracy of two bTMB cutoffs was established against TMB derived from FoundationOne, an analytically validated TMB platform. Precision was evaluated by comparing the reproducibility of bTMB calls across replicate samples. We also retrospectively analyzed plasma samples from the OAK (NCT02008227) and POPLAR (NCT01903993) trials with the bTMB assay to determine the association of bTMB with atezolizumab clinical activity. The biomarker evaluable population (BEP) included 211 patients in POPLAR (intention-to-treat [ITT] =287) and 583 patients in OAK (excludes patients with known EGFR/ALK mutations; ITT=850), with blood samples available for targeted genomic sequencing. Assay positivity was defined as the presence of a number of somatic base substitutions greater than or equal to the bTMB cutoffs. Results: The average positive percent agreement (PPA), negative percent agreement (NPA) and positive predictive value (PPV) across the bTMB cutoffs were 95%, 100% and 100%, respectively. The average precision was 96%, with a coefficient of variation of 7%. The assay limit of detection was defined as 1% tumor content in at least 20 ng of cfDNA. In POPLAR, improved progression-free survival (PFS) and overall survival (OS) hazard ratios (HRs) with atezolizumab vs docetaxel were observed for patients with bTMB at or above a range of bTMB thresholds compared with the ITT and BEP populations. In OAK, PFS benefit with atezolizumab vs docetaxel was observed at bTMB thresholds ≥10 (cut point ≥10: HR 0.73; n=251) compared with BEP (HR 0.87, 95% CI 0.73-1.04; n=585). bTMB did not correlate with PD-L1 expression as measured by VENTANA SP142 immunohistochemistry. Conclusions: We have developed and analytically validated a blood-based assay to determine TMB with high accuracy and precision, using as little as 1% tumor content in a sample with 20 ng of cfDNA. Retrospective analyses from POPLAR and OAK data provide the first demonstrations that blood-based measurement of TMB may be associated with atezolizumab clinical efficacy in second-line NSCLC. Thus, the bTMB assay may provide a non-invasive biomarker to identify patients who derive clinical benefit from single agent PD-1/PD-L1 inhibition. Prospective studies using bTMB are currently ongoing in patients with first-line NSCLC, including BFAST and B-F1RST (NCT02848651). Citation Format: Daniel S. Lieber, Emily White, Jacob Silterra, Shan Zhong, Tina Brennan, Michael Coyne, Mark Kennedy, David R. Gandara, Marcin Kowanetz, Sarah M. Paul, Erica Schleifman, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Lukas Amler, Todd Riehl, Craig Cummings, Priti S. Hegde, Wei Zou, Alan Sandler, Marcus Ballinger, Tony Mok, David S. Shames, Doron Lipson, Christine Malboeuf, David Fabrizio. Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2017 Oct 1-4; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2018;6(9 Suppl):Abstract nr A41." @default.
• W2896812842 created "2018-10-26" @default.
• W2896812842 creator A5000413092 @default.
• W2896812842 creator A5001204975 @default.
• W2896812842 creator A5001816288 @default.
• W2896812842 creator A5002641296 @default.
• W2896812842 creator A5007455008 @default.
• W2896812842 creator A5016568716 @default.
• W2896812842 creator A5021287587 @default.
• W2896812842 creator A5028478747 @default.
• W2896812842 creator A5029135141 @default.
• W2896812842 creator A5029183165 @default.
• W2896812842 creator A5036091074 @default.
• W2896812842 creator A5036391595 @default.
• W2896812842 creator A5040846333 @default.
• W2896812842 creator A5041853768 @default.
• W2896812842 creator A5043917346 @default.
• W2896812842 creator A5046304194 @default.
• W2896812842 creator A5049192558 @default.
• W2896812842 creator A5053359122 @default.
• W2896812842 creator A5064263842 @default.
• W2896812842 creator A5066717752 @default.
• W2896812842 creator A5071586460 @default.
• W2896812842 creator A5074479466 @default.
• W2896812842 creator A5084619380 @default.
• W2896812842 creator A5087092015 @default.
• W2896812842 creator A5087172750 @default.
• W2896812842 creator A5088627335 @default.
• W2896812842 date "2018-09-01" @default.
• W2896812842 modified "2023-10-18" @default.
• W2896812842 title "Abstract A41: Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC" @default.
• W2896812842 doi "https://doi.org/10.1158/2326-6074.tumimm17-a41" @default.
• W2896812842 hasPublicationYear "2018" @default.
• W2896812842 type Work @default.
• W2896812842 sameAs 2896812842 @default.
• W2896812842 citedByCount "0" @default.
• W2896812842 crossrefType "proceedings-article" @default.
• W2896812842 hasAuthorship W2896812842A5000413092 @default.
• W2896812842 hasAuthorship W2896812842A5001204975 @default.
• W2896812842 hasAuthorship W2896812842A5001816288 @default.
• W2896812842 hasAuthorship W2896812842A5002641296 @default.
• W2896812842 hasAuthorship W2896812842A5007455008 @default.
• W2896812842 hasAuthorship W2896812842A5016568716 @default.
• W2896812842 hasAuthorship W2896812842A5021287587 @default.
• W2896812842 hasAuthorship W2896812842A5028478747 @default.
• W2896812842 hasAuthorship W2896812842A5029135141 @default.
• W2896812842 hasAuthorship W2896812842A5029183165 @default.
• W2896812842 hasAuthorship W2896812842A5036091074 @default.
• W2896812842 hasAuthorship W2896812842A5036391595 @default.
• W2896812842 hasAuthorship W2896812842A5040846333 @default.
• W2896812842 hasAuthorship W2896812842A5041853768 @default.
• W2896812842 hasAuthorship W2896812842A5043917346 @default.
• W2896812842 hasAuthorship W2896812842A5046304194 @default.
• W2896812842 hasAuthorship W2896812842A5049192558 @default.
• W2896812842 hasAuthorship W2896812842A5053359122 @default.
• W2896812842 hasAuthorship W2896812842A5064263842 @default.
• W2896812842 hasAuthorship W2896812842A5066717752 @default.
• W2896812842 hasAuthorship W2896812842A5071586460 @default.
• W2896812842 hasAuthorship W2896812842A5074479466 @default.
• W2896812842 hasAuthorship W2896812842A5084619380 @default.
• W2896812842 hasAuthorship W2896812842A5087092015 @default.
• W2896812842 hasAuthorship W2896812842A5087172750 @default.
• W2896812842 hasAuthorship W2896812842A5088627335 @default.
• W2896812842 hasConcept C121608353 @default.
• W2896812842 hasConcept C126322002 @default.
• W2896812842 hasConcept C143998085 @default.
• W2896812842 hasConcept C152110520 @default.
• W2896812842 hasConcept C172680121 @default.
• W2896812842 hasConcept C2775949291 @default.
• W2896812842 hasConcept C2776256026 @default.
• W2896812842 hasConcept C2777701055 @default.
• W2896812842 hasConcept C2778258057 @default.
• W2896812842 hasConcept C2779234561 @default.
• W2896812842 hasConcept C2780057760 @default.
• W2896812842 hasConcept C2781197716 @default.
• W2896812842 hasConcept C535046627 @default.
• W2896812842 hasConcept C54355233 @default.
• W2896812842 hasConcept C55493867 @default.
• W2896812842 hasConcept C71924100 @default.
• W2896812842 hasConcept C86803240 @default.
• W2896812842 hasConceptScore W2896812842C121608353 @default.
• W2896812842 hasConceptScore W2896812842C126322002 @default.
• W2896812842 hasConceptScore W2896812842C143998085 @default.
• W2896812842 hasConceptScore W2896812842C152110520 @default.
• W2896812842 hasConceptScore W2896812842C172680121 @default.
• W2896812842 hasConceptScore W2896812842C2775949291 @default.
• W2896812842 hasConceptScore W2896812842C2776256026 @default.
• W2896812842 hasConceptScore W2896812842C2777701055 @default.
• W2896812842 hasConceptScore W2896812842C2778258057 @default.
• W2896812842 hasConceptScore W2896812842C2779234561 @default.
• W2896812842 hasConceptScore W2896812842C2780057760 @default.
• W2896812842 hasConceptScore W2896812842C2781197716 @default.
• W2896812842 hasConceptScore W2896812842C535046627 @default.
• W2896812842 hasConceptScore W2896812842C54355233 @default.
• W2896812842 hasConceptScore W2896812842C55493867 @default.
• W2896812842 hasConceptScore W2896812842C71924100 @default.
• W2896812842 hasConceptScore W2896812842C86803240 @default.
• W2896812842 hasLocation W28968128421 @default.
• W2896812842 hasOpenAccess W2896812842 @default.
• W2896812842 hasPrimaryLocation W28968128421 @default.

• next